Tildrakizumab
- TRADE NAME: Ilumya (Merck Sharpe & Dohme)
- INDICATIONS: Moderate-to-severe plaque psoriasis
- CLASS: Interleukin-23 inhibitor, Monoclonal antibody
- HALF-LIFE: 23 days
FDA APPROVAL DATE: 03/20/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Live vaccines
PREGNANCY CATEGORY: N/A
Insufficient data to inform drug-associated risk
Please login to see the rest of this drug profile
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tildrakizumab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric